Buying guide
Versius vs Johnson & Johnson Ottava in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
Key differences
On DEPLOY's record, Versius is further along: at the commercial stage versus Johnson & Johnson Ottava at the pilot stage, as of 2026.
- Versius has more verified real-world deployments (5 vs 3).
- Versius is at the commercial stage; Johnson & Johnson Ottava at the pilot stage.
| Attribute | ||
|---|---|---|
| Manufacturer | CMR Surgical | Johnson & Johnson |
| Form factor | surgical | surgical |
| Maturity | commercial | pilot |
| Autonomy | ◐ not independently verified | — |
| Availability | internal-onlyenterprise | internal-onlyenterprise |
| Price | $750,000-$1,000,000 (analyst estimate) | Not announced |
| Capability claims |
| — |
| Brain | — | — |
| Verified deployments | 5 | 3 |
| Privacy practices | — | — |
| Sources on file | 25 | 4 |
Track this matchup
Get told the moment Versius or Johnson & Johnson Ottava changes. Verified changes only, the second they are real. No press-release noise.
Versius
Johnson & Johnson Ottava
Editorial summaries
Versius
CMR Surgical's Versius (and Versius Plus) is a modular, multi-arm, soft-tissue minimal-access surgical robot from UK-based CMR Surgical, and the international-soft-tissue archetype of DEPLOY's surgical cluster. Its modular multi-arm architecture is a deliberate contrast to the monolithic design of Intuitive's da Vinci: it is teleoperated and software-driven, capturing telematic, video, and outcome data.
On regulatory status (a correction worth recording): Versius is US-FDA-cleared for cholecystectomy via a De Novo authorization in October 2024, with Versius Plus cleared via 510(k) on December 18, 2025 (also cholecystectomy) and a gynecology 510(k) submitted April 29, 2026 (pending); it is not broadly 'US-pending', only the gynecology indication is. It is CE-marked and commercial across Europe, Latin America, AMEA, and Australia. As enterprise B2B surgical equipment sold to hospitals, there is no consumer price.
Johnson & Johnson Ottava
J&J MedTech's Ottava is a soft-tissue general-surgery robotic platform with four arms integrated into the operating table, announced in 2020. It is pre-market: J&J submitted a De Novo request to the FDA in January 2026, and Ottava is not authorized to be marketed. DEPLOY classifies it research tier: J&J's corporate scale does not translate into verified surgical-robotics deployment, because the gating event (FDA clearance) has not occurred.
By the framework, Ottava sits at the same research tier as far smaller pre-market entrants. There is no price; it is not sold.
Common questions
How do Versius and Johnson & Johnson Ottava differ?
What is the difference between Versius and Johnson & Johnson Ottava?
Is Versius or Johnson & Johnson Ottava more autonomous?
Which has more verified deployments, Versius or Johnson & Johnson Ottava?
Recent coverage
- OTTAVA Surgical Robotics Integrates Robotic Arms and Motion ControlJohnson & Johnson Ottava · TimesTech · 2026-10-29
- Stryker invests $400M into CMR SurgicalVersius · The Robot Report · 2026-10-15
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJohnson & Johnson Ottava · MarketBeat · 2026-10-13
- Stryker to Invest $400M in CMR Surgical, Gains U.S. Sales Rights and Acquisition OptionVersius · The AI Insider · 2026-10-12
Related comparisons
- Versius vs da Vinci (and Ion)
- Versius vs Stryker Mako SmartRobotics
- Versius vs Hugo RAS
- Versius vs mBos TKA System
- Versius vs Maestro
- Versius vs CORI
- Versius vs ROSA
- da Vinci (and Ion) vs Johnson & Johnson Ottava
- Stryker Mako SmartRobotics vs Johnson & Johnson Ottava
- Hugo RAS vs Johnson & Johnson Ottava
- mBos TKA System vs Johnson & Johnson Ottava
- Maestro vs Johnson & Johnson Ottava
Keep researching
Keep reading
Ask the registry
For AI assistants
Use DEPLOY in Claude, Cursor, and other AI assistants
Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.
Machine-readable: this page as markdown.

